Published in Cytokine Growth Factor Rev on June 01, 1996
Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta-mediated signal transduction. Mol Cell Biol (1999) 3.55
Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am J Pathol (2002) 2.23
In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A (1999) 2.17
Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol Biol Cell (2003) 2.11
miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. J Biol Chem (2010) 2.05
Transforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-beta. Breast Cancer Res (2000) 1.54
TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway. Gastroenterology (2009) 1.50
Bone morphogenetic protein signaling and growth suppression in colon cancer. Am J Physiol Gastrointest Liver Physiol (2006) 1.45
Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer (1999) 1.44
Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A (2000) 1.43
The role of DNA damage repair in aging of adult stem cells. Nucleic Acids Res (2007) 1.35
Proliferating bile duct epithelial cells are a major source of connective tissue growth factor in rat biliary fibrosis. Am J Pathol (2001) 1.32
Jab1/CSN5, a component of the COP9 signalosome, regulates transforming growth factor beta signaling by binding to Smad7 and promoting its degradation. Mol Cell Biol (2004) 1.30
Loss of TGF-beta signaling contributes to autoimmune pancreatitis. J Clin Invest (2000) 1.18
TGF-beta receptor levels regulate the specificity of signaling pathway activation and biological effects of TGF-beta. Biochim Biophys Acta (2009) 1.16
Transforming growth factor-beta and breast cancer: Transforming growth factor-beta/SMAD signaling defects and cancer. Breast Cancer Res (2000) 1.11
Attenuated transforming growth factor beta signaling promotes nuclear factor-kappaB activation in head and neck cancer. Cancer Res (2009) 1.11
Protein kinase C betaII and TGFbetaRII in omega-3 fatty acid-mediated inhibition of colon carcinogenesis. J Cell Biol (2002) 1.08
Mouse models of gastric cancer. Cancers (Basel) (2013) 1.07
Blockade of TSP1-dependent TGF-β activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy. Am J Pathol (2011) 1.06
Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta. Am J Pathol (2004) 1.02
TGF-beta signaling and the role of inhibitory Smads in non-small cell lung cancer. J Thorac Oncol (2010) 1.00
HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells. Breast Cancer Res (2005) 1.00
Effect of in vivo loss of GDF-15 on hepatocellular carcinogenesis. J Cancer Res Clin Oncol (2008) 1.00
Expression of transforming growth factor beta in renal cell carcinoma and matched non-involved renal tissue. Urol Res (2004) 0.95
Role of Radiation-induced TGF-beta Signaling in Cancer Therapy. Mol Cell Pharmacol (2009) 0.95
Associated changes of lipid peroxidation and transforming growth factor beta1 levels in human colon cancer during tumour progression. Gut (2002) 0.94
Vascular endothelial growth factor induces CXCL1 chemokine release via JNK and PI-3K-dependent pathways in human lung carcinoma epithelial cells. Int J Mol Sci (2013) 0.93
Down-regulation of transforming growth factor-beta type II receptor (TGF-betaRII) protein and mRNA expression in cervical cancer. Mol Cancer (2008) 0.91
Epigenetic Targeting of Transforming Growth Factor β Receptor II and Implications for Cancer Therapy. Mol Cell Pharmacol (2009) 0.90
Upregulated SMAD3 promotes epithelial-mesenchymal transition and predicts poor prognosis in pancreatic ductal adenocarcinoma. Lab Invest (2014) 0.88
FasL gene knock-down therapy enhances the antiglioma immune response. Neuro Oncol (2010) 0.86
TGF-β/Smad3 inhibit vascular smooth muscle cell apoptosis through an autocrine signaling mechanism involving VEGF-A. Cell Death Dis (2014) 0.86
Towards a vaccine to prevent cancer in Lynch syndrome patients. Fam Cancer (2013) 0.86
Therapeutical measures to control airway tolerance in asthma and lung cancer. Front Immunol (2012) 0.86
Disruption of transforming growth factor beta signaling by a novel ligand-dependent mechanism. J Exp Med (2002) 0.85
Transfection of the type II TGF-beta receptor into colon cancer cells increases receptor expression, inhibits cell growth, and reduces the malignant phenotype. Ann Surg (1998) 0.84
Transforming growth factor beta receptor 2 (TGFBR2) changes sialylation in the microsatellite unstable (MSI) Colorectal cancer cell line HCT116. PLoS One (2013) 0.84
TGFbeta signaling supports survival and metastasis of endometrial cancer cells. Cancer Manag Res (2009) 0.84
Expression and mutational analysis of TGF-beta/Smads signaling in human cervical cancers. J Gynecol Oncol (2009) 0.84
MiR-17-5p regulates cell proliferation and migration by targeting transforming growth factor-β receptor 2 in gastric cancer. Oncotarget (2016) 0.83
Autocrine Transforming Growth Factor-beta Growth Pathway in Murine Osteosarcoma Cell Lines Associated with Inability to Affect Phosphorylation of Retinoblastoma Protein. Sarcoma (2000) 0.82
TGFbeta-mediated signaling and transcriptional regulation in pancreatic development and cancer. Curr Opin Gastroenterol (2001) 0.82
Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells. J Cell Mol Med (2012) 0.82
NF-κB induces miR-148a to sustain TGF-β/Smad signaling activation in glioblastoma. Mol Cancer (2015) 0.81
Transforming growth factor beta can be a parameter of aggressiveness of pT1 colorectal cancer. World J Gastroenterol (2005) 0.81
Identification of a series of transforming growth factor beta-responsive genes by retrovirus-mediated gene trap screening. Mol Cell Biol (2000) 0.81
Investigation of three new mouse mammary tumor cell lines as models for transforming growth factor (TGF)-beta and Neu pathway signaling studies: identification of a novel model for TGF-beta-induced epithelial-to-mesenchymal transition. Breast Cancer Res (2004) 0.80
Relation between transforming growth factor-β1 expression, its receptor and clinicopathological factors and survival in HER2-negative gastric cancers. Wien Klin Wochenschr (2011) 0.80
p15(INK4b) in bladder carcinomas: decreased expression in superficial tumours. Br J Cancer (2001) 0.80
Cooperative assembly of Co-Smad4 MH1 with R-Smad1/3 MH1 on DNA: a molecular dynamics simulation study. PLoS One (2013) 0.80
Cytoplasmic DRAK1 overexpressed in head and neck cancers inhibits TGF-β1 tumor suppressor activity by binding to Smad3 to interrupt its complex formation with Smad4. Oncogene (2014) 0.79
TGF-beta and p53 staining in CT-guided and endoscopic ultrasound fine-needle aspirates of pancreatic adenocarcinoma. Dig Dis Sci (2004) 0.79
Rapid induction of p21WAF1 but delayed down-regulation of Cdc25A in the TGF-beta-induced cell cycle arrest of gastric carcinoma cells. Br J Cancer (1999) 0.78
Gasdermin C Is Upregulated by Inactivation of Transforming Growth Factor β Receptor Type II in the Presence of Mutated Apc, Promoting Colorectal Cancer Proliferation. PLoS One (2016) 0.77
TGFbeta1 expression in colonic mucosa: modulation by dietary lipids. Genes Nutr (2007) 0.77
Transforming growth factor β signaling pathway associated gene polymorphisms may explain lower breast cancer risk in western Indian women. PLoS One (2011) 0.77
Expression of nonsteroidal anti-inflammatory drug-activated gene-1 (NAG-1) inversely correlates with tumor progression in gastric adenomas and carcinomas. J Cancer Res Clin Oncol (2008) 0.77
Restoring TGFbeta function in microsatellite unstable (MSI-H) colorectal cancer reduces tumourigenicity but increases metastasis formation. Int J Colorectal Dis (2008) 0.77
Growth factor mediated signaling in pancreatic pathogenesis. Cancers (Basel) (2011) 0.76
Transforming growth factor beta 1 and sodium butyrate differentially modulate urokinase plasminogen activator and plasminogen activator inhibitor-1 in human breast normal and cancer cells. Br J Cancer (1998) 0.76
Transforming growth factors-beta are not good biomarkers of chemopreventive efficacy in a preclinical breast cancer model system. Breast Cancer Res (2000) 0.75
p53/TGF-beta/cancer: an intriguing connection. Cytokine Growth Factor Rev (1996) 0.75
Expression analysis of the TGF-β/SMAD target genes in adenocarcinoma of esophagogastric junction. Open Med (Wars) (2016) 0.75
Regulating the availability of transforming growth factor ß1 in B104 neuroblastoma cells. Exp Neurol (2010) 0.75
A novel model of colitis-associated cancer in SAMP1/YitFc mice with Crohn's disease-like ileitis. PLoS One (2017) 0.75
Galunisertib (LY2157299), a transforming growth factor-β receptor I kinase inhibitor, attenuates acute pancreatitis in rats. Braz J Med Biol Res (2016) 0.75
Nilotinib, a tyrosine kinase inhibitor exhibits protection against acute pancreatitis-induced lung and liver damage in rats. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.75
Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A (1986) 12.14
Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A (1993) 10.82
Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature (1985) 10.13
Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med (1986) 9.86
Regulation of immune responses by TGF-beta. Annu Rev Immunol (1998) 8.01
Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci U S A (1987) 6.43
Autocrine growth factors and cancer. Nature (1985) 5.97
Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci U S A (1985) 5.93
New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc Natl Acad Sci U S A (1981) 5.89
Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol (1999) 5.58
Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J (1999) 5.49
Human transforming growth factor-alpha: precursor structure and expression in E. coli. Cell (1984) 5.39
Some recent advances in the chemistry and biology of transforming growth factor-beta. J Cell Biol (1987) 5.25
Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol (1986) 5.19
Transforming growth factor-beta: biological function and chemical structure. Science (1986) 5.08
Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci U S A (1992) 4.94
A nuclear factor 1 binding site mediates the transcriptional activation of a type I collagen promoter by transforming growth factor-beta. Cell (1988) 3.72
Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst (2000) 3.63
Immunodetection and quantitation of the two forms of transforming growth factor-beta (TGF-beta 1 and TGF-beta 2) secreted by cells in culture. J Cell Physiol (1989) 3.58
Transforming growth factor-beta 1: histochemical localization with antibodies to different epitopes. J Cell Biol (1989) 3.55
Polypeptide transforming growth factors isolated from bovine sources and used for wound healing in vivo. Science (1983) 3.51
Purification and properties of a type beta transforming growth factor from bovine kidney. Biochemistry (1983) 3.49
Role of transforming growth factor-beta in the development of the mouse embryo. J Cell Biol (1987) 3.48
Transforming growth factors: isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction. Proc Natl Acad Sci U S A (1980) 3.45
Transforming growth factors from neoplastic and nonneoplastic tissues. Fed Proc (1983) 3.31
Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol (1986) 3.29
Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A (1995) 3.25
Transforming growth factor-beta: recent progress and new challenges. J Cell Biol (1992) 3.18
Transforming growth factor beta 1 positively regulates its own expression in normal and transformed cells. J Biol Chem (1988) 3.13
Sarcoma growth factor from conditioned medium of virally transformed cells is composed of both type alpha and type beta transforming growth factors. Proc Natl Acad Sci U S A (1983) 3.02
Functional characterization of transforming growth factor beta signaling in Smad2- and Smad3-deficient fibroblasts. J Biol Chem (2001) 2.85
Expression of transforming growth factor-beta 1 in specific cells and tissues of adult and neonatal mice. J Cell Biol (1989) 2.77
Role of retinoids in differentiation and carcinogenesis. Cancer Res (1983) 2.74
Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex. Mol Cell Biol (1990) 2.73
Peptide growth factors are multifunctional. Nature (1988) 2.71
Synergistic interaction of two classes of transforming growth factors from murine sarcoma cells. Cancer Res (1982) 2.70
Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J Immunol (1988) 2.70
Mesoderm induction in amphibians: the role of TGF-beta 2-like factors. Science (1988) 2.68
Peptide growth factors and inflammation, tissue repair, and cancer. J Clin Invest (1986) 2.40
Characterization of the promoter region of the human transforming growth factor-beta 1 gene. J Biol Chem (1989) 2.40
Identification of multiple active growth factors in basement membrane Matrigel suggests caution in interpretation of cellular activity related to extracellular matrix components. Exp Cell Res (1992) 2.38
Transforming growth factor-beta controls receptor levels for epidermal growth factor in NRK fibroblasts. Cell (1984) 2.30
Maternal rescue of transforming growth factor-beta 1 null mice. Science (1994) 2.28
Anchorage-independent growth of synoviocytes from arthritic and normal joints. Stimulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-beta and retinoids. J Clin Invest (1989) 2.28
Transforming growth factor-beta and the initiation of chondrogenesis and osteogenesis in the rat femur. J Cell Biol (1990) 2.19
A novel mitochondrial septin-like protein, ARTS, mediates apoptosis dependent on its P-loop motif. Nat Cell Biol (2000) 2.17
Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest (1989) 2.16
Regulated expression and growth inhibitory effects of transforming growth factor-beta isoforms in mouse mammary gland development. Development (1991) 2.02
Osteoblasts synthesize and respond to transforming growth factor-type beta (TGF-beta) in vitro. J Cell Biol (1987) 2.01
Transforming growth factor-beta. A very potent inhibitor of myoblast differentiation, identical to the differentiation inhibitor secreted by Buffalo rat liver cells. J Biol Chem (1986) 1.99
Transforming growth factor beta: biochemistry and roles in embryogenesis, tissue repair and remodeling, and carcinogenesis. Recent Prog Horm Res (1988) 1.99
Promoter sequences of the human transforming growth factor-beta 1 gene responsive to transforming growth factor-beta 1 autoinduction. J Biol Chem (1989) 1.97
Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta. Proc Natl Acad Sci U S A (1994) 1.87
Targeting expression of a transforming growth factor beta 1 transgene to the pregnant mammary gland inhibits alveolar development and lactation. EMBO J (1993) 1.86
A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res (1999) 1.85
Isolation from murine sarcoma cells of novel transforming growth factors potentiated by EGF. Nature (1982) 1.79
Alpha and beta human transforming growth factors stimulate prostaglandin production and bone resorption in cultured mouse calvaria. Proc Natl Acad Sci U S A (1985) 1.75
Targeted mutagenesis of Smad1 reveals an essential role in chorioallantoic fusion. Dev Biol (2001) 1.71
Transforming growth factor beta. A biologic chorioretinal glue. Arch Ophthalmol (1989) 1.71
The Smad4 activation domain (SAD) is a proline-rich, p300-dependent transcriptional activation domain. J Biol Chem (2000) 1.70
Incisional wound healing in transforming growth factor-beta1 null mice. Wound Repair Regen (2000) 1.69
Post-transcriptional regulation of the human transforming growth factor-beta 1 gene. J Biol Chem (1992) 1.68
Inhibition of skin development by overexpression of transforming growth factor beta 1 in the epidermis of transgenic mice. Proc Natl Acad Sci U S A (1993) 1.68
TGF-beta 1 prevents hypertrophy of epiphyseal chondrocytes: regulation of gene expression for cartilage matrix proteins and metalloproteases. Dev Biol (1993) 1.67
Increased secretion of type beta transforming growth factor accompanies viral transformation of cells. Mol Cell Biol (1985) 1.65
Transforming growth factor-beta in human aqueous humor. Curr Eye Res (1990) 1.65
Transforming growth factor beta 1 (TGF-beta 1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-beta 1 null mouse phenotype. Proc Natl Acad Sci U S A (1993) 1.64
X-linked inhibitor of apoptosis protein functions as a cofactor in transforming growth factor-beta signaling. J Biol Chem (2001) 1.63
Regulation of transforming growth factor beta 1 gene expression by the product of the retinoblastoma-susceptibility gene. Proc Natl Acad Sci U S A (1991) 1.63
Characterization of functional domains within Smad4/DPC4. J Biol Chem (1997) 1.60
TGF-beta: problems and prospects. Cell Regul (1990) 1.59
cDNA cloning of porcine transforming growth factor-beta 1 mRNAs. Evidence for alternate splicing and polyadenylation. J Biol Chem (1988) 1.58
Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases. Genes Dev (1998) 1.58
Overexpression of transforming growth factor beta1 in arterial endothelium causes hyperplasia, apoptosis, and cartilaginous metaplasia. Proc Natl Acad Sci U S A (1998) 1.58
Complementary deoxyribonucleic acid cloning of a novel transforming growth factor-beta messenger ribonucleic acid from chick embryo chondrocytes. Mol Endocrinol (1988) 1.57
Differential responsiveness of myc- and ras-transfected cells to growth factors: selective stimulation of myc-transfected cells by epidermal growth factor. Mol Cell Biol (1986) 1.57
The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic mice. Proc Natl Acad Sci U S A (1996) 1.56
Factors involved in the differentiation of TGF-beta-producing cells from naive CD4+ T cells: IL-4 and IFN-gamma have opposing effects, while TGF-beta positively regulates its own production. J Immunol (1998) 1.56
Complementary deoxyribonucleic acid cloning of a messenger ribonucleic acid encoding transforming growth factor beta 4 from chicken embryo chondrocytes. Mol Endocrinol (1988) 1.56
Characterization of the mouse transforming growth factor-beta 1 promoter and activation by the Ha-ras oncogene. Mol Cell Biol (1991) 1.55
Localization and actions of transforming growth factor-beta s in the embryonic nervous system. Development (1991) 1.53
Transforming growth factor beta regulates the metabolism of proteoglycans in bovine cartilage organ cultures. J Biol Chem (1988) 1.53
Inhibition of growth by transforming growth factor-beta following fusion of two nonresponsive human carcinoma cell lines. Implication of the type II receptor in growth inhibitory responses. J Biol Chem (1992) 1.52
Hypoxia upregulates the synthesis of TGF-beta 1 by human dermal fibroblasts. J Invest Dermatol (1991) 1.52
Activation of the second promoter of the transforming growth factor-beta 1 gene by transforming growth factor-beta 1 and phorbol ester occurs through the same target sequences. J Biol Chem (1989) 1.51
Smad3/AP-1 interactions control transcriptional responses to TGF-beta in a promoter-specific manner. Oncogene (2001) 1.51
Sandwich enzyme-linked immunosorbent assays (SELISAs) quantitate and distinguish two forms of transforming growth factor-beta (TGF-beta 1 and TGF-beta 2) in complex biological fluids. Growth Factors (1989) 1.45
Perinatal mortality in Type 2 diabetes mellitus. Diabet Med (2000) 1.45
Human transforming growth factor-alpha causes precocious eyelid opening in newborn mice. Nature (1985) 1.44
Antibodies to peptide determinants in transforming growth factor beta and their applications. Biochemistry (1988) 1.43
Autoimmunity associated with TGF-beta1-deficiency in mice is dependent on MHC class II antigen expression. J Clin Invest (1996) 1.42
Transcriptional activating activity of Smad4: roles of SMAD hetero-oligomerization and enhancement by an associating transactivator. Proc Natl Acad Sci U S A (1998) 1.41
Fetal movement and breathing. Midwife Health Visit Community Nurse (1978) 1.40
Transforming growth factor-beta. Multiple actions and potential clinical applications. JAMA (1989) 1.40
Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells. Cancer Immunol Immunother (1988) 1.39
Sorting nexin 6, a novel SNX, interacts with the transforming growth factor-beta family of receptor serine-threonine kinases. J Biol Chem (2001) 1.38
cDNA cloning by PCR of rat transforming growth factor beta-1. Nucleic Acids Res (1990) 1.35
Serine phosphorylation, chromosomal localization, and transforming growth factor-beta signal transduction by human bsp-1. J Biol Chem (1996) 1.34